Changing treatment: latest news

Changing treatment resources

Changing treatment features

Changing treatment in your own words

Changing treatment news from aidsmap

More news

Changing treatment news selected from other sources

  • Effective treatments available for HIV patients not eligible for efavirenz regimens

    HIV drug regimens that do not include efavirenz are effective as first-line antiretroviral therapy, a new American clinical trial found. The finding is important for patients who are not eligible for treatment with efavirenz, including women considering becoming pregnant and patients with a history of severe psychiatric disorders.

    07 October 2014 | Science Daily
  • Switch From Efavirenz to Rilpivirine Quells CNS Toxicity, Improves Sleep

    Switching from Atripla (efavirenz plus tenofovir/emtricitabine [TDF/FTC]) to Complera (Eviplera, rilpivirine plus TDF/FTC) significantly relieved central nervous system (CNS) toxicity and improved sleep in people with those problems while taking Atripla [1]. All but 1 of 40 study participants who switched in this London/Brighton study maintained virologic control through 24 weeks.

    16 September 2014 | NATAP
  • Switch from single-tablet regimen to 3 tablets works in Denmark

    Switching from an efavirenz-containing single-tablet regimen (STR) to an efavirenz containing triple-tablet regimen (TTR) to save money maintained viral suppression in Denmark. Antiretroviral-naive people who started the TTR attained the same virologic suppression rate as people who started the STR combination.

    10 July 2014 | International AIDS Society
  • New ARV prescribing guidelines for London (2014)

    The guidelines are the result of a therapeutic tender, which encourages drug manufacturers to offer volume discounts for different stages of the treatment pathway, for example, for preferred use in first-line, second-line and multiple resistant treatment.

    01 July 2014 | HIV i-Base
  • Viral load rebounds in 35% of people using PI/r monotherapy: results of five-year PIVOT study

    A long-term strategy study sponsored by the Medical Research Council (MRC) in the UK reported low rates of serious complications and the potential to reduce drug costs. However, more than a third of people on the PI/r monotherapy group had viral load rebound compared to only 3% of people on standard combination therapy.

    10 March 2014 | HIV i-Base
  • U.S. FDA Approves Gilead’s Once-Daily Single Tablet HIV-1 Regimen Complera® for Patients Switching from a Stable Regimen

    European Commission Also Approves Expanded Indication for Regimen, Marketed as Eviplera® in the European Union.

    16 December 2013 | Gilead press release
  • Once-daily raltegravir for 48 weeks as maintenance therapy in Paris

    Sixty-eight of 71 people who switched to once-daily raltegravir with a viral load below 50 copies maintained virologic suppression for 48 weeks in an observational study at a Paris hospital. Virologic failure occurred in 3 people taking nucleos(t)ides with raltegravir who had a previous nucleos(t)ide failure.

    22 October 2013 | NATAP
  • TDF/FTC-to-ABC/3TC switch maintains viral suppression, eases bone markers

    A switch from tenofovir/emtricitabine (TDF/FTC) to abacavir/lamivudine (ABC/3TC), both with atazanavir/ritonavir, maintained viral suppression through 48 weeks in a noninferiority analysis and improved bone and kidney markers. Four people in the ABC/3TC arm (2%) and one in the TDF/FTC arm (1%) had study-defined virologic failure by week 48.

    19 September 2013 | NATAP
  • Switching From Efavirenz to Rilpivirine Combo Quells CNS Side Effects

    Swapping efavirenz-containing Atripla for rilpivirine-containing Complera (Eviplera in Europe) significantly lowered rates of central nervous system (CNS) side effects and sleep disturbances in a 40-person multicenter pilot trial.

    13 September 2013 | NATAP
  • Lessons Learned When the Labs Go Awry

    David Fawcett describes the feelings - and the lessons - when a rebound in viral load resulted in a change of his HIV medication.

    10 September 2013 |
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.